Targets › NR3C4
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Genitourinary, Other; next expected readout Dec 2026.
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling…. (UniProt, P10275)
Open in Phaseline: the race on NR3C4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Boehringer Ingelheim | BI 690517 Finerenone-like non-steroidal mineralocorticoid receptor antagonist | NR3C4 | Phase 3 | Kidney Disease, Chronic | Dec 2026 |
| Pr. Nicolas GIRERD | Potassium Canrenoate Mineralocorticoid receptor (MR) antagonist | NR3C4 | Phase 2 | Brain-dead Organ Donors | Dec 2033 |
Kidney Disease, Chronic (1) Brain-dead Organ Donors (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.